Pathogenesis and progression of chronic myeloid leukemia

Haematologica

Volumn 81, Issue 1, 1996, Pages 63-76

  Santucci, Maria Alessandra ^a,c   Saglio, Giuseppe ^b   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTOKINE; PROTEIN TYROSINE KINASE;

CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; GENE REARRANGEMENT; HEMATOPOIESIS; HUMAN; IMMUNOLOGICAL TOLERANCE; PATHOGENESIS;

DISEASE PROGRESSION; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PROTO-ONCOGENE PROTEINS C-ABL;

EID: 0030324678     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1497-9.
2. Groffen J, Stephenson JR, Heisterkamp N, deKlein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9.
3. Clark SS, Crist WM, Witte ON. Molecular pathogenesis of Ph-positive leukemias. Annu Rev Med 1989; 40:113-22.
4. Dubè ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC. Cytogenetic studies of early myeloid progenitor compartments in Phi-positive chronic myeloid leukemia. II. Long-term culture reveals the persistence of Ph1-negative progenitors in treated as well as newly diagnosed patients. Blood 1984; 63: 1172-7.
5. Dubè ID, Arlin ZA, Kalousek DK, Eaves CJ, Eaves AC. Non clonal hemopoietic progenitor cells detected in long-term marrow cultures from a Turner syndrome mosaic with chronic myeloid leukemia. Blood 1984; 64:1284-7.
6. Verfaille CM, Miller WJ, Boylan K, McGlave PB. Selection of benign hematopoietic progenitors in Chronic Myelogenous Leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79:1003-10.
7. +/CD38 lo population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization. Blood 1995; 86:737-43.
8. Martinelli G, Lemoli RM, Farabegoli P, et al. Peristence of non clonal hematopoietic progenitor cells in blastic phase of chronic myelogenous leukemia. Haematologica 1994; 79:445-7.
9. Udomsakdi C, Eaves CJ, Landsorp PM, Eaves AC. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 1992; 80:2522-30.
10. Bedi A, Zehnbauer BA, Collector MI, et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993; 81:2898-902.
11. + cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994; 83:1744-51.
12. Diamond J, Goldman JM, Melo JV. BCR-ABL, ABL-BCR, BCR and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood 1995; 85:2171.
13. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science 1990; 247:1079-82.
14. Laneuville P, Heisterkamp N, Groffen J. Expression of the chronic myeloid leukemia-associated p210 BCR/ABL oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 1991; 6:275-82.
15. Carlesso N, Griffin JD, Druker BJ. Use of a temperature-sensitive mutant to define the biological effects of the p210 bcr-abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 1994; 9:149-56.
16. Laneuville P, Sun G, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3-independent growth by retroviral transduction and expression of p210 bcr/abl. Blood 1992; 80:1788-97.
17. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein on K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37:1035-42.
18. Heisterkamp N, Stay G, Groffen J, deKlein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph1 translocation. Nature 1985; 315:758-61.
19. Puil L, Liu J, Gish G, et al. Bcr-abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13:764-73.
20. McWhirter J, Wang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 1991; 11:1553-72.
21. Lu D, Liu J, Campbell M, et al. Tyrosine phosphorylation of p160 bcr by p210 bcr-abl. Blood 1993; 82:1257-63.
22. Nichols G, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia. Blood 1994; 84:2912-8.
23. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia: leukemia. Blood 1994; 84:1731-6.
24. Hallek M, Warmuth M, Danhauser-Riedl S, et al. The src-family kinase p53/p56lyn associates with and is activated by the p210 bcr/abl kinase. (Abstract) Blood 1994; 84:294a.
25. Hallek M, Danhauser-Riedl S, Herbst R, et al. The receptor tyrosine kinase p145 c-kit interacts with the p210 bcr/abl kinase in myeloid cells. (Abstract) Blood 1994; 84:293a.
26. Maru Y, Peters KL, Afar DEH, Shibuya M, Witte ON, Smithgall TE. Tyrosine phosphorylation of bcr by FPS/FES protein-tyrosine kinases induces association of bcr with GRB-2/SOS. Mol Cell Biol 1995; 15:835-42.
27. Reuter GW, Fu H, Cripe LD, Collier RJ, Pendergast AM. Association of the protein kinases c-bcr and bcr-abl with proteins of the 14-3-3 family. Science 1994; 266:129-33.
28. Braselmann S, McCormick F. BCR and RAF form a complex in vivo via 14-3-3 proteins. EMBO J 1995; 14:4839-48.
29. Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B, Griffin JD. Tyrosine phosphorylation of p95vav in myeloid cells is regulated by GM-CSF, IL-3 and Steel factor and is constitutively increased by p210 bcr/abl. EMBO J 1995; 14:257-65.
30. Skorski T, Kanakaraj P, Nieborowska M, et al. Phosphatidyl-inositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood 1995; 86:726-36.
31. Salgia R, Li JL, Brunkhorst B, et al. Molecular cloning of paxillin, a focal adhesion phosphoprotein involved in growth factor receptor and oncogene signal transduction in hematopoietic cells (Abstract). Blood 1994; 84:375a.
32. Mandanas RA, Leibowitz DS, Gharehbaghi K, et al. Role of p21 Ras in p210 bcr-abl transformation in murine myeloid cells. Blood 1993; 82:1838-47.
33. Upadhyaya G, Guba SC, Sih SA, et al. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88:2131-6.
34. DeChatelet LR, Cooper MR, McCall CE. Absence of measurable leukocyte alkaline phosphatase activity from leukocytes of patients with chronic granulocytic leukemia. Clin Chem 1970; 16:798-9.
35. Schofield R. The relationship between the spleen colony-forming cell and the hematopoietic stem cell. Blood Cells 1978; 4:7-25.
36. Verfaule CM, Benis A, Iida J, McGlave PB, McCarthy JB. Adhesion of committed human hematopoietic progenitors to synthetic peptides from the C-terminal heparin-binding domain of fibronectin: cooperation between the integrin 41 and the CD44 adhesion receptors. Blood 1994; 84:1802-11.
37. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukemia. Nature 1987; 328:342-4.
38. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. ProcNatl Acad Sci USA 1986; 83:5306-10.
39. Verfaille CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992; 90:1232-41.
40. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. Bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179-87.
41. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia. Blood 1994; 83:2038-44.
42. Greenberg BR, Wilson FD, Woo L, Jenks HM. Cytogenetics of fibroblastic colonies in Ph1 positive chronic myelogenous leukemia. Blood 1978; 51:1039-44.
43. O'Brien S, Kantarjian H, Shtalrid M, Blick M, Beran M, Talpaz M. Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Hematol Pathol 1988; 2:25-34.
44. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaille CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85:3636-45.
45. Wetzler M, Kurzrock R, Taylor K, et al. Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. Cancer Res 1990; 50:5801-5.
46. Agarwal R, Doren S, Hicks B, Dunbar CE. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 1995; 85:1306-12.
47. Dowding C, Guo AP, Osterholz J, Sicczkowski M, Goldman J, Gordon M. Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78:499-505.
48. Lundell BI, McCarthy JB, Kovach NL, Verfaille CM. Activation of the 1 integrins restores integrin dependent and independent adhesion of CML progenitors to fibronectin. (Abstract). Exp Hematol 1994; 771.
49. Bhatia R, McGlave PB, Verfaille CM. Interferon-α treatment of normal bone marrow stroma results in enhanced adhesion of chronic myelogenous leukemia hematopoietic progenitors via mechanisms involving MIP-1 and TGF-β. (Abstract) Exp Hematol 1994; 797.
50. Santucci MA, Soligo D, Pileri S, Zuffa E, Testoni N, Tura S. Interferon-α effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk Lymphoma 1993; 11:113-8.
51. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Aleration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 1991; 78:2400-6.
52. Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991; 78:1476-84.
53. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82:2273-7.
54. Chen W, Peace DJ, Rovira DK, You SG, Cheever MA. T-cell immunity to the joining region of p210 bcr-abl protein. Proc Natl Acad Sci USA 1992; 89:1468-72.
55. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85:2680-4.
56. Momigliano Richiardi P, Tosi R, Martinelli G, et al. The HLA class I-CML association revised taking into account the two forms of gene fusion in the Philadelphia chromosome: a multicenter study. Leukemia 1994; 8:2134-7.
57. Daley GQ, Van Etten R, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-30.
58. Daley GQ, Van Etten R, Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1991; 88:11335-8.
59. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of bcr-abl-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993; 90:3755-9.
60. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
61. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992; 256:835-9.
62. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia. Interferon-alpha 2a as compared with conventional chemotherapy for the treatment of chronic myelogenous leukemia. N Engl J Med 1994; 330:820-5.
63. Pichert G, Alyea EP, Soiffer RJ, Roy DC, Ritz J. Persistence of myeloid progenitor cells expressing bcr-abl mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 84:2109-14.
64. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-8.